---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-116856"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:35:42.085043+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Erasca reports 40% response rate in NRAS Q61X melanoma cohort from Phase 1b SEACRAFT-1 trial

## Summary
- 40% (4/10) response rate in efficacy-evaluable NRAS Q61X melanoma patients; 3 confirmed partial responses, 1 unconfirmed.
- 70% (7/10) of patients remained on treatment as of September 5, 2024 efficacy cutoff.
- Mandatory primary rash prophylaxis reduced skin toxicities and drug discontinuation rate vs. prior Novartis trials.
- Company expects SEACRAFT-2 Phase 3 randomized dose optimization data readout in 2025.

## SEC filing metadata
- accession: 0000950170-24-116856
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017024116856/0000950170-24-116856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017024116856/eras-20241024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-116856
- JSON: https://secwatch.observer/filing/0000950170-24-116856.json
- Plain text: https://secwatch.observer/filing/0000950170-24-116856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.